Alpha Teknova
Yahoo Finance • 3 days ago
Teknova targets less than $8M 2026 free cash outflow as it lifts revenue guide to $45M-$47M
Earnings Call Insights: Alpha Teknova (TKNO) Q2 2026 MANAGEMENT VIEW * Stephen Gunstream (President, CEO & Director) said, “Revenue grew 18% compared to the second quarter 2025, exceeding $12 million for the quarter, the highest quarte... Full story
Yahoo Finance • 3 days ago
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as c... Full story
Yahoo Finance • 5 months ago
Teknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilities
Earnings Call Insights: Alpha Teknova, Inc. (TKNO) Q4 2025 MANAGEMENT VIEW * CEO Stephen Gunstream indicated that 2025 marked "another year of strong all-around execution for Teknova," highlighting accelerated top line revenue growth o... Full story
Yahoo Finance • 8 months ago
Alpha Teknova Among 3 Penny Stocks Worth Noting
As the U.S. stock market experiences a mixed performance with major indices like the Dow Jones and S&P 500 showing gains, while tech-heavy sectors face challenges, investors are exploring diverse opportunities. Penny stocks, though an olde... Full story
Yahoo Finance • 9 months ago
Teknova Reports Third Quarter 2025 Financial Results
Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (... Full story
Yahoo Finance • 9 months ago
Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025
HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecula... Full story
Yahoo Finance • 11 months ago
Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks
The stock market’s largest players – companies like Nvidia and its trillion-dollar peers – often dominate the headlines and attract most of the capital. Yet, some of the most compelling opportunities can be found at the smaller end of the... Full story
Yahoo Finance • 11 months ago
Does Alpha Teknova (TKNO) Have Meaningful Growth Opportunities?
Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund underperformed and generated a net return of +9.6% compared to a total retu... Full story
Yahoo Finance • last year
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecul... Full story
Yahoo Finance • last year
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies
HOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product... Full story
Yahoo Finance • last year
Teknova Reports Fourth Quarter and Full Year 2024 Financial Results
Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidance Fourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior year Company provides 2025 revenue guidance of $39-42 mil... Full story
Yahoo Finance • last year
Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecula... Full story
Yahoo Finance • 3 years ago
Teknova Reports Third Quarter 2023 Financial Results
Raised $22.9 million of equity capital, paid down $10.0 million of long-term debt Third quarter 2023 total revenue was $8.2 million, down 24% from prior year Expect 2023 revenue at the low end of previously announced guidance range of $37-... Full story
Yahoo Finance • 3 years ago
Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023
HOLLISTER, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecula... Full story
Yahoo Finance • 3 years ago
Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development
HOLLISTER, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, a... Full story
Yahoo Finance • 3 years ago
Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility
HOLLISTER, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecula... Full story
Yahoo Finance • 3 years ago
Teknova Announces Up to $22.9 Million Concurrent Registered Direct Offering and Private Placement
HOLLISTER, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecula... Full story
Yahoo Finance • 3 years ago
Teknova Announces New Board Member, Martha J. Demski
HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular... Full story
Yahoo Finance • 3 years ago
Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development
HOLLISTER, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, an... Full story
Yahoo Finance • 3 years ago
Teknova Reports First Quarter 2023 Financial Results
First quarter 2023 total revenue was $9.1 million, up 16% sequentially Launch of proprietary AAV-Tek™ Solutions gene therapy product line Company reaffirms 2023 revenue guidance of $42-46 million HOLLISTER, Calif., May 10, 2023 (GLOBE... Full story